Literature DB >> 1765970

Does estrogen replacement therapy protect against rheumatoid arthritis?

T D Spector1, P Brennan, P Harris, J W Studd, A J Silman.   

Abstract

The incidence of rheumatoid arthritis (RA) was compared in 2 cohorts of women aged 35-64. One consisted of 1,075 estrogen replacement therapy (ERT) users and the other was 3,251 women from general practice registers. Screening detected 32 cases; 8 postmenopausal control and 6 ERT women developed RA during the study period 1982-1986. This produced incidence rates of 19.7/10,000 and 12.3/10,000 years of observation for ERT and controls, respectively. The relative risks for ERT was 1.62 (95% CI 0.56-4.74) and reduced towards unity after adjustment for potential confounders. Despite the wide confidence interval, our data do not support the previous observation of a 4-fold reduction in RA incidence in ERT users. Indeed the incidence rate in the exposed group in this study exceeded current population estimates of RA incidence in postmenopausal women. We believe that the high incidence rates could be best explained by the self-selection for estrogen therapy at the menopause of those with undiagnosed joint symptoms. These findings underscore the difficulties in elucidating the relationship between ERT and RA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1765970

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  Association Between Menopausal Factors and the Risk of Seronegative and Seropositive Rheumatoid Arthritis: Results From the Nurses' Health Studies.

Authors:  Camilla Bengtsson; Susan Malspeis; Cecilia Orellana; Jeffrey A Sparks; Karen H Costenbader; Elizabeth W Karlson
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-09-21       Impact factor: 4.794

2.  Why the gender difference in susceptibility to rheumatoid arthritis?

Authors:  P Brennan; A Silman
Journal:  Ann Rheum Dis       Date:  1995-09       Impact factor: 19.103

3.  Effects of postmenopausal hormone therapy on rheumatoid arthritis: the women's health initiative randomized controlled trials.

Authors:  Brian Walitt; Mary Pettinger; Arthur Weinstein; James Katz; James Torner; Mary Chester Wasko; Barbara V Howard
Journal:  Arthritis Rheum       Date:  2008-03-15

4.  The relationship between osteoarthritis and osteoporosis in the general population: the Chingford Study.

Authors:  D J Hart; I Mootoosamy; D V Doyle; T D Spector
Journal:  Ann Rheum Dis       Date:  1994-03       Impact factor: 19.103

5.  High Follicle-Stimulating Hormone Level Associated With Risk of Rheumatoid Arthritis and Disease Activity.

Authors:  Xianhui Zhang; Pengyan Qiao; Qianyu Guo; Zixie Liang; Jie Pan; Fengping Wu; Xuexue Wang; Liyun Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-22       Impact factor: 6.055

6.  Postmenopausal hormone therapy and the risk of rheumatoid arthritis: results from the Swedish EIRA population-based case-control study.

Authors:  Cecilia Orellana; Saedis Saevarsdottir; Lars Klareskog; Elizabeth W Karlson; Lars Alfredsson; Camilla Bengtsson
Journal:  Eur J Epidemiol       Date:  2015-03-12       Impact factor: 8.082

7.  Menopausal factors and risk of seropositive rheumatoid arthritis in postmenopausal women: a nationwide cohort study of 1.36 million women.

Authors:  Yeonghee Eun; Keun Hye Jeon; Kyungdo Han; Dahye Kim; Hyungjin Kim; Jaejoon Lee; Dong-Yun Lee; Jung Eun Yoo; Dong Wook Shin
Journal:  Sci Rep       Date:  2020-11-27       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.